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Abstract
Mechanical circulatory support (MCS) devices, such as left ventricular assist devices
(LVADs) are very useful in improving outcomes in patients with advanced-stage heart
failure. Despite recent advances in LVAD development, pump thrombosis is one of
the most severe adverse events caused by LVADs. The contact of blood with artificial
materials of LVAD pumps and cannulas triggers the coagulation cascade. Heat spots,
for example, produced by mechanical bearings are often subjected to thrombus buildup when low-flow situations impair washout and thus the necessary cooling does
not happen. The formation of thrombus in an LVAD may compromise its function,
causing a drop in flow and pumping power leading to failure of the LVAD, if left unattended. If a clot becomes dislodged and circulates in the bloodstream, it may disturb
the flow or occlude the blood vessels in vital organs and cause internal damage that
could be fatal, for example, ischemic stroke. That is why patients with LVADs are on
anti-coagulant medication. However, the anti-coagulants can cause a set of issues
for the patient—an example of gastrointestinal (GI) bleeding is given in illustration.
On account of this, these devices are only used as a last resort in clinical practice.
It is, therefore, necessary to develop devices with better mechanics of blood flow,
performance and hemocompatibility. This paper discusses the development of LVADs
through landmark clinical trials in detail and describes the evolution of device design
to reduce the risk of pump thrombosis and achieve better hemocompatibility. Whilst
driveline infection, right heart failure and arrhythmias have been recognised as LVAD-
related complications, this paper focuses on complications related to pump thrombosis, especially blood coagulopathy in detail and potential strategies to mitigate this
complication. Furthermore, it also discusses the LVAD implantation techniques and
their anatomical challenges.
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provided the original work is properly cited.
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I NTRO D U C TI O N

pumps designed to augment the function of the failing heart in order
to re-establish normal hemodynamic and end-organ blood flow and

Heart failure (HF) is a complex clinical syndrome that is identified by

may provide support to either left (LVAD), right (RVAD) or both ven-

the reduced ability of the heart to fill and/or pump blood (Coronel

tricles (BiVAD) (Cai et al., 2017; Hosseinipour et al., 2017). TAHs,

et al., 2001; Savarese & Lund, 2017; Tan et al., 2010). From a physi-

on the other hand, replace a portion or the entire heart, similar to

ological point of view, HF may be defined as an inadequate cardiac

a prosthesis elsewhere in the human body. Since the first implanta-

output to meet the body's metabolic demands, or an adequate car-

tion in 1966, LVADs have become an established worldwide treat-

diac output secondary to compensatory activation, which tends

ment modality for HF patients (Chair et al., 2016; DeBakey, 1971;

to manifest as increased left ventricular filling pressures (Rosalia

Hosseinipour et al., 2017; Prinzing et al., 2016). These devices may

et al., 2021; Savarese & Lund, 2017).

be employed as a ‘bridge to transplantation (BTT)’, whereby they

HF is a leading cause of death worldwide, constituting a major

provide mechanical support to the heart for patients awaiting trans-

clinical and public health problem, with a prevalence in excess of

plantation, a ‘bridge to recovery (BTR), where mechanical support

26 million people (Savarese & Lund, 2017). It is estimated that HF

provided by them allows for sufficient myocardial recovery follow-

currently affects 6.3 million individuals in the United States, with a

ing which the device can be removed, or as a ‘destination therapy

projected 46% increase to over 9 million people by the year 2030

(DT)’, where mechanical support is provided for patients who are

(Levine & Gass, 2019). This trajectory is due to a number of factors,

deemed ineligible for transplantation due to age, malignancy or other

for example, an ageing population, the pervasiveness of HF risk fac-

co-morbidities (Chair et al., 2016; Holley et al., 2014; Lahpor, 2009;

tors, such as hypertension, coronary artery disease and obesity. The

Rodriguez et al., 2013).

economic burden created by HF is also significant. In the US alone,

Hence, MCS devices like LVADs are very useful in improving out-

the annual total direct medical costs for patients with HF currently

comes in patients with advanced-stage heart disease, however, their

stand at $39 billion and are expected to increase to $53 billion by the

use is limited by not only their mechanical features, for example, large

year 2030 (Rosalia et al., 2021).

size and a lack of durability, but also because of potential complica-

Developments in the area of HF pharmacotherapy, especially

tions (Bartoli & Dowling, 2019). Despite recent advances in LVAD

localised delivery of various therapeutics, for example, proteins,

development, pump thrombosis is one of the most severe adverse

drugs and stem cells to the heart, targeting various pathophysiolog-

events caused by LVADs. All VAD systems activate the blood coag-

ical aspects of the HF are substantial (Hameed et al., 2019; Kathryn

ulation system via several mechanisms. The blood contact with the

et al., 2021). However, they may not be an option for advanced-stage

artificial materials of VAD pumps and cannulas triggers the coagula-

HF patients. Advanced or medically refractory HF represents the

tion cascade as well as high shear stress due to high flow velocities,

end-stage form of heart disease, and carries a life expectancy of less

small gaps or high-speed moving parts, such as the impeller of the

than 2 years (Combes, 2017; Kennelly et al., 2021). While heart trans-

rotary blood pumps (Potapov et al., 2017; van Oeveren, 1995). Areas

plantation remains the ‘gold standard’ for definitive treatment, this

of flow stagnation represent preferred thrombus developing sites as

treatment modality is significantly limited due to the severe imbal-

well as areas with recirculation vortices within the pump. Heat spots,

ance between donor heart supply and demand (Cai et al., 2017; Siân

for example, produced by mechanical bearings are often subjected

Pincott & Burch, 2011). In the US alone, approximately 3200 ortho-

to thrombus build-up when low-flow situations impair washout and

tropic heart transplantations are performed annually, despite an es-

thus the necessary cooling does not happen (Potapov et al., 2017).

timated 250,000 patients with New York Heart Association (NYHA)

The formation of thrombosis in an LVAD may compromise its func-

class IIIB or IV symptoms that are refractory to medical treatment,

tion, causing a drop in flow and pumping power leading to failure of

making such patients potential candidates for heart transplantation

the LVAD, if left unattended (Singhvi & Trachtenberg, 2019). If the

(Ahmed, 2007; Alraies & Eckman, 2014). Furthermore, many pa-

clot becomes dislodged and circulates in the bloodstream, it may dis-

tients deteriorate while awaiting a donor heart to become available,

turb the flow or occlude the blood vessels in vital organs and cause

culminating in irreversible multi-organ failure, rendering them an

internal damage that could be fatal. That is why patients with LVADs

unsuitable candidate for a transplant. This discrepancy, along with

are on anticoagulant medication.

the increasing incidence of HF has prompted efforts towards the de-

On account of this, these devices are only used as a last resort

velopment of alternative approaches, namely mechanical circulatory

in clinical practice. It is, therefore, necessary to develop devices

support (MCS) devices to minimise the mortality rates.

with better mechanisms of blood flow, performance and hemocom-

While each MCS device has its own unique characteristics, most

patibility. This paper describes the development of LVADs through

systems can be classified into two categories: Ventricular assist de-

landmark clinical trials in detail and describes the evolution of device

vices (VADs) and total artificial hearts (TAH). VADs are mechanical

design to reduce the risk of pump thrombosis and achieve better
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hemocompatibility. Whilst driveline infection, right heart failure and

The trial demonstrated a dramatic 48% reduction in all-cause

arrhythmias have been recognised as LVAD-related complications,

mortality in the LVAD group compared to the medical-therapy group

this paper focuses on complications related to pump thrombosis,

(relative risk, 0.52; 95% confidence interval 0.34–0.78; p = 0.001).

especially blood coagulopathy in detail and potential strategies to

The rates of survival were superior in the device group at 1 year

mitigate this complication. Furthermore, it also discusses the LVAD

(52% vs. 25%, p = 0.002) and 2 years (23% vs. 8%, p = 0.09), respec-

implantation techniques and their anatomical challenges.

tively, while compared to the medical therapy group, a meaningful
improvement in quality of life was observed in the device group.

2 | LE F T V E NTR I CU L A R A S S I S T D E V I C E
DESIGN

On the basis of these results, the HeartMate XVE received FDA approval, and LVADs were deemed an acceptable alternative therapy
for chronic HF patients (Chair et al., 2016). Despite this substantial
survival benefit, the frequency of serious adverse events in the de-

Since its inception in 1962, all generations of implantable LVAD tech-

vice group was 2.35 times that in the medical therapy group.

nology have the same three essential components: an inflow cannula

First-generation LVADs succumbed to a limited lifetime and low

in the left ventricle, a pump and an outflow graft, which delivers

reliability due to extensive mechanical wear and failure on repeat-

blood to the arterial circulation through the aorta. The pump is, in

edly moving parts, such as diaphragms, valves and bearings (Cai

turn, powered via a tunnelled driveline that connects to an external

et al., 2017; Levine & Gass, 2019). Due to their large volume, exten-

controller and power source (Levine & Gass, 2019).

sive surgical dissection was necessary to create the pump pocket,
which posed a high risk for driveline infection, bleeding and throm-

2.1 | First-generation LVADs

boembolic complications (Birks, 2010; Lahpor, 2009). Consequently,
initial VADs were limited to recipients who had a body surface area
of at least 1.5 m2 to accommodate the device, thereby restricting

First-generation LVADs, otherwise known as volume displacement

women and adolescents from device candidacy (Cai et al., 2017).

pumps, were designed to replicate the native cardiopulmonary

With the risks of these extensive device complications, this pulsatile

circulation by driving pulsatile blood flow via a pulse generator

pump design was not a preferable option for long-term support.

(Lahpor, 2009; Levine & Gass, 2019). These pumps incorporated unidirectional inlet and outlet valves, along with a moveable diaphragm
that could be displaced to periodically/cyclically increase the inter-

2.2 | Second-generation LVADs

nal pump volume to facilitate blood filling during the diastolic phase
while subsequently compressing in order to eject blood during the

Following the REMATCH trial, second-generation LVADs were

systolic phase (Cai et al., 2017; Levine & Gass, 2019). These pumps

developed with a focus on miniaturisation, improved efficiency

were connected to an external driver, either a pneumatic or an elec-

and greater mechanical reliability, in order to combat the adverse

trical pump, which provided alternating pressures required to gener-

events associated with first-generation devices (Cai et al., 2017;

ate the characteristic pulsatile flow (Cai et al., 2017). Examples of

Levine & Gass, 2019). This paradigm shift saw the introduction of

first-generation LVADs include the HeartMate XVE (Thoratec Inc.),

rotary pumps, which operated via continuous blood flow as op-

Abiomed AB5000 (Abiomed Inc.), Berlin Heart EXCOR (Berlin Heart

posed to the characteristic pulsatile flow generated by their pulsatile

Inc.).

predecessor(s), as shown in Figure 1 (Levine & Gass, 2019; Slaughter
et al., 2009).
The rotary heart pump design may be classified into two cat-

2.1.1 | REMATCH trial—Demonstrated clinical
efficacy of LVADs

egories based on the pump's structure: axial flow pumps and centrifugal pumps. In terms of pump design theory, axial flow pumps
typically generate higher flows at lower pressure rises, while centrif-

The landmark clinical trial that launched the LVAD into widespread

ugal pumps are capable of producing higher pressures at lower flows

clinical use was the Randomized Evaluation of Mechanical Assistance

(Hosseinipour et al., 2017; Shah et al., 2017). All second-generation

for the Treatment of Congestive Heart Failure (REMATCH) trial,

pumps are based on axial flow pump technology, which consists of

published in the New England Journal of Medicine in 2001 (Levine

a single rotating element, known as the impeller, suspended by me-

& Gass, 2019; Rose et al., 2001). The primary objective of the

chanical contact bearings within a stationary housing unit, which

REMATCH trial was to evaluate the reliability and effectiveness of

directs continuous flow linearly along the axis of rotation (Levine &

LVADs in chronic end-stage heart failure patients (class IV, as per

Gass, 2019).

New York Heart Association scale) from May 1998 to July 2001

Much of the success of second-generation LVADs stems from

(Chair et al., 2016; Rose et al., 2001). A total of 129 patients deemed

the simplicity of their design. Pump miniaturisation was achieved by

ineligible for cardiac transplantation were randomised to either

eliminating extraneous components such as valves and compliance

LVAD implantation with the HeartMate XVE device (68 patients) or

chamber (Cai et al., 2017; Chair et al., 2016). This reduction in size

optimal medical therapy (61 patients).

is highly advantageous as it increases the versatility of the patient

4
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F I G U R E 1 (a) Pulsatile flow, (b) continuous flow—left ventricular assist device (adapted from Slaughter et al. (2009)

cohort, while also facilitating less invasive surgical procedures,

second-generation device, with over 2500 implants worldwide

thereby improving patient comfort and decreasing the risk of infec-

(Garbade et al., 2011).

tion. Furthermore, by relying on a single moving part, the continuous flow second-generation LVADs possess greater durability and
enhanced mechanical reliability due to lower mechanical wear and

2.2.1 | HeartMate II trial

tear on moving parts (Levine & Gass, 2019). Examples of second generation devices include the HeartMate™ II (Thoratec Inc.), the Jarvik

One of the initial trials that launched the era of second-generation

2000® (Jarvik Heart, Inc.) and the DeBakey® LVAD (MicroMed

LVAD devices was the ‘Advanced Heart Failure Treated with

Technology, Inc.). To date, the HeartMate II is the most successful

Continuous-Flow Left Ventricular Assist Device study, published in

|
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2009 by Slaughter et al (Slaughter et al., 2009). In this randomised,

These results emphasise the importance of LVAD implantation tech-

multicentre trial, a total of 200 patients with end-stage HF were

niques, adequate anti-coagulation treatment including post-operative

randomly assigned to undergo implantation of a continuous flow

heparin bridging, and optimal speed management (<9000 RPMs)

HeartMate LVAD (n = 134), or its pulsatile flow predecessor, the

(Cai et al., 2017; Levine & Gass, 2019; Maltais et al., 2017).

HeartMate XVE (n = 66). The primary composite endpoint was, at
2 years, survival free of disabling stroke, or reoperation to repair or
replace the pump (Slaughter et al., 2009).

2.3 | Third-generation LVADs

At 2 years, the trial showed that the primary composite endpoint
was achieved in more patients with the continuous flow HeartMate

The transition from second- to third-generation rotary blood

II device, compared to the pulsatile flow Heartmate XVE device (46%

pumps is defined by the introduction of magnetic and/or hydro-

vs. 11%, respectively, p < 0.001), with rates of survival alone also

dynamic bearing technology, whereby the impeller is suspended

being superior in the HeartMate II group (58% vs. 24%, p = 0.008)

entirely within the blood field (Hosseinipour et al., 2017; Levine &

(Slaughter et al., 2009). Moreover, the frequency of adverse events,

Gass, 2019). The elimination of all mechanical contacts between

including infection (device-and non-device-related), right heart fail-

the impeller and the drive mechanism enables friction-free rota-

ure and cardiac arrhythmia, and the need for device replacements

tion of the impeller with minimal heat generation, leading to in-

were significantly lower in the continuous flow group, while the

creased mechanical durability necessary for long-term mechanical

quality of life and functional capacity improved significantly in both

circulatory support, with estimated reliability of 10 years (Levine &

groups compared to baseline (Slaughter et al., 2009). Interestingly,

Gass, 2019; Prinzing et al., 2016). Moreover, the elimination of me-

the incidence of stroke did not differ significantly between the con-

chanical contact bearings allows for a more complete washing of the

tinuous-f low group and the pulsatile-flow group (0.13 vs. 0.22 events

blood-contacting surfaces, preventing the incidence of stasis and re-

per patient-year, respectively, p = 0.21) (Slaughter et al., 2009).

circulation vortices in pro-thrombotic sites, thereby enhancing pump

Despite overcoming many of the shortcomings of their first-

biocompatibility (Levine & Gass, 2019).

generation counterparts, second-generation LVADs succumb to

In contrast to second-generation LVADs, which consist of

several limitations. The impeller, which rotates at high speeds of

axial-flow pumps, third-generation LVADs operate exclusively via

10,000–20,000 rpm, is culpable for generating excessive amounts of

a centrifugal pump, where the rotating impeller propels blood per-

shear stresses, which over time may lead to serious adverse events

pendicular to the axis of rotation via centrifugal force (Hosseinipour

such as hemolysis, thrombus formation and device failure, restrict-

et al., 2017; Moazami et al., 2013). Centrifugal flow pumps offer

ing the efficacy of the pump (Nguyen et al., 2016). In order to miti-

certain advantages over axial flow pumps, including lower rota-

gate the risk of thrombosis, patients with second-generation LVADs

tional speeds and greater afterload sensitivity, that is, demonstrate

often require high doses of anticoagulants, which increases their

more significant changes in flow for a given change in pressure. For

risks of bleeding. Regurgitation is also possible due to the lack of

this reason, centrifugal pumps can decrease inlet suction force at

valves to prevent backflow.

times of low flow; reducing the risk of ventricular arrhythmias (Cai

The clinical manifestation of pump thrombosis took the forefront

et al., 2017; Moazami et al., 2013).

for HeartMate II LVADs in 2014 (Levine & Gass, 2019). While initial

With the introduction of third-generation LVADs, another sig-

trials demonstrated low rates of pump thrombosis, an apparent in-

nificant size reduction could be achieved. Unlike first- and second-

crease in the rate of pump thrombosis at the Cleveland Clinic led to the

generation devices, which are positioned in a sub-diaphragmatic

pooling of data with two other major centres, Barnes-Jewish Hospital

pocket, third-generation pumps sit entirely within the pericardial

(Washington University School of Medicine) and Duke University

space, which reduces the risks of infection and surgical trauma

Medical Centre, for the landmark report by Starling et al (Starling

(Levine & Gass, 2019). Examples of third-generation devices are

et al., 2014). From March 2011, Starling et al reported an abrupt in-

the VentrAssist™ (Ventracor Ltd., Sydney, Australia), DuraHeart™

crease in the incidence of pump thrombosis, with rates of pump throm-

(Terumo, Inc.), the HVAD (HeartWare Corp.) and the EVAHEART™

bosis increases from 2.2% to 8.4% over a 3-month period (Starling

LVAS (Sun Medical Technology Research Corporation).

et al., 2014). This increased rate of pump thrombosis brought with it
a substantial increase in morbidity and mortality. At 180-days post-
implantation, patient mortality was more than twofold higher than in

2.3.1 | ADVANCE trial

patients without thrombosis (35.6% vs. 16.8%) (Starling et al., 2014).
These results led to significant changes in clinical practice protocols,

The ADVANCE trial was the initial trial that launched the era of

highlighted by the PRE-VENT (Prevention of HeartMate II Pump

third-generation centrifugal flow pumps (Cai et al., 2017; Levine &

Thrombosis through Clinical Management) trial, which was designed

Gass, 2019). In this study, patients with end-stage HF who were

with the aim of lowering the rates of pump thrombosis in HeartMate

deemed eligible for cardiac transplantation were implanted with the

II device (Maltais et al., 2017). By adhering to this pre-determined

HVAD device (n = 140) and compared to a control cohort (n = 499)

set of surgical and subsequent clinical management practices, lower

from the Interagency Registry for Mechanically Assisted Circulatory

rates of early pump thrombosis with HeartMate II may be achieved.

Support (INTERMACS) registry who received a commercially

6
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available LVAD, the second generation HeartMate II as a BTT (Levine

subjects was reduced by 24.2% in ENDURANCE Supplemental com-

& Gass, 2019; Najjar et al., 2014).

pared with ENDURANCE (p = 0.10), with hemorrhagic stroke being

The trial confirmed HVAD non-inferiority to the control device, with 90.7% success defined by transplant, recovery explant

reduced by 50.5% (10.5% vs. 5.2%, p = 0.02) (Levine & Gass, 2019;
Milano et al., 2018).

or survival with HVAD at six months in the study arm versus
90.1% (p < 0.001) in the control group (Najjar et al., 2014; Nguyen
et al., 2016). Regression analysis at 30, 60, 120 and 360 days post-
enrolment consistently showed equivalent survival in the HVAD

2.5 | Centrifugal vs axial flow pump—
MOMENTUM 3 study

and control groups (Cai et al., 2017; Najjar et al., 2014). Secondary
endpoints of functional capacity and quality-of-life scores improved

In the Multicenter Study of MagLev Technology in Patients

markedly, with a favourable adverse event profile, similar to those

Undergoing

obtained with cardiac transplantation (Najjar et al., 2014). The re-

HeartMate 3 (MOMENTUM 3), the HeartMate 3 centrifugal-flow

sults of this trial led to FDA approval of HVAD for BTT in 2012, along

left ventricular assist device was compared with the HeartMate II

with a subsequent Continued Access Protocol (CAP) trial for the BTT

axial-flow device in terms of safety and efficacy (Levine & Gass, 2019,

indication (Najjar et al., 2014).

Tamez et al., 2017, Mehra et al., 2018). In order to determine the

Mechanical

Circulatory

Support

Therapy

with

safety and efficacy of the Heartmate 3 device, 1020 patients with

2.4 | Second-generation vs third-generation
LVADs—Endurance trial

advanced-stage heart failure were randomised in a 1:1 ratio and
implanted with either the HeartMate 3 (n = 515) or HeartMate II
(n = 505) pump, irrespective of the intended goal of use (bridge to
transplantation or destination therapy) (Mehra et al., 2018).

The first head-to-head trial between second-and third-generation

At 2 years, the HeartMate 3 proved superior to the HeartMate

LVADs was the ENDURANCE trial, published in 2017 (Levine &

II with respect to the primary endpoint, with 76.9% of patients in

Gass, 2019). Here, 446 advanced heart failure patients were ran-

the HeartMate 3 group achieving survival free of death, disabling

domly assigned, in a 2:1 ratio, to the investigational centrifugal flow

stroke or reoperation to remove or replace a malfunctioning device,

HVAD or the control HeartMate II, an axial flow device (Levine &

as compared to 64.8% in the latter (p < 0.001 for superiority) (Cai

Gass, 2019; Milano et al., 2018; Rogers et al., 2017).

et al., 2017; Levine & Gass, 2019; Mehra et al., 2018). The rate of

The HVAD demonstrated non-inferiority to the control with re-

pump replacement was significantly lower in the centrifugal pump

spect to overall survival 2 years post-enrollment (55.0% vs. 57.4%,

group than in the axial flow pump group (2.3% vs. 11.3%, p < 0.001),

p = 0.006) (Rogers et al., 2017). Quality of life and functional capac-

which was primarily driven by a 12.5% absolute reduction in pump

ity improved to a similar degree in the two cohorts. Interestingly,

thrombosis rates with the HeartMate 3, (1.4% vs. 13.9%, p < 0.001)

fewer patients in the study arm experienced device malfunction or

(Mehra et al., 2018). This virtual elimination of pump thrombosis

device failure requiring urgent explantation or transplantation than

may be largely attributed to the technological advancements and

did patients who received the study device (16.2% vs. 8.8%). As a re-

improved design of the third-generation centrifugal pump over its

sult, the rate of pump replacement for the HVAD was lower than for

axial predecessor (Levine & Gass, 2019). With large gaps within the

HeartMate II (7.8% vs. 13.4%, p = 0.06). While it was anticipated that

blood flow path and a contactless impeller design, shear stresses

the bearing-less design of the HVAD would bring lower rates of pump

within the pump are reduced, while the artificial pulse ensures a

thrombosis, no significant difference was apparent between the two

thorough washing of blood-contacting surfaces to reduce the risk

cohorts. However, rates of stroke were alarmingly higher in the HVAD

of blood stasis (Levine & Gass, 2019). Moreover, the rates of adverse

group (29.7% vs. 12.1%, p < 0.001), both for ischemic stroke (17.6% vs.

events, including stroke of any kind, major bleeding and gastrointes-

8.1%, p = 0.007) and hemorrhagic stroke (14.9% vs. 4.0%, p < 0.001)

tinal haemorrhage, were consistently lower in the centrifugal-flow

(Cai et al., 2017; Levine & Gass, 2019; Rogers et al., 2017). Post hoc

pump group than in the axial-flow pump group (Mehra et al., 2018).

analyses revealed increased mean arterial blood pressure (<90 mmHg)
as a significant independent risk factor for stroke (Rogers et al., 2017).
These results led to the follow-up Endurance Supplemental trial,
a prospective, multicentre study evaluation that aimed to evaluate

3 | A DV E R S E E V E NT S — LVA D - R E L ATE D
B LO O D COAG U LO PATH Y

the impact of blood pressure management on stroke rates in patients
receiving the HeartWare HVAD System (Levine & Gass, 2019). The

Despite advances in the LVAD field and their great benefit, their use

trial confirmed that by adhering to a blood pressure management

is associated with complications, for example, pump thrombosis,

protocol, maintaining mean arterial pressure –MAP <90 mmHg, the

stroke, bleeding, infection, right heart failure, aortic insufficiency

HVAD demonstrated superiority in terms of freedom from death,

and arrhythmias (Cook et al., 2017; Han et al., 2018; Kilic et al., 2015;

disabling stroke and device replacement or urgent transplantation

Ozcan & Deshmukh, 2020). Figure 2 shows the LVAD-related com-

(76.1% vs. 66.9%, p = 0.04), which was the primary endpoint of

plications and their incidence rates. Early detection and manage-

the original ENDURANCE trial. The incidence of stroke in HVAD

ment of these complications are crucial to improve the outcome.
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F I G U R E 2 LVAD-related complications and their incidence rates. Arrhythmias (Ozcan & Deshmukh, 2020), right heart failure (Han
et al., 2018; Kilic et al., 2015), gastrointestinal bleeding (Goldstein et al., 2015; Stulak et al., 2014), stroke (Han et al., 2018; Rogers
et al., 2017), pump thrombosis (Cook et al., 2017), driveline infections (Rogers et al., 2017). LVAD, left ventricular assist device

3.1 | Pump thrombosis

low pump flow, thereby reducing the unloading of the left ventricle, which will manifest as signs of heart failure in the patient.

Pump thrombosis is a relatively frequent complication with a re-

Symptoms such as dyspnea, weakness or dizziness may occur,

ported incidence of 5.5%–12.2% and is associated with significant

and ultimately, patient may go into cardiogenic shock (Potapov

morbidity (Cook et al., 2017). Numerous factors contribute towards

et al., 2017).

this complication. They can be device-related, including outflow
graft kinking, extrinsic compression, low pump speed and local heat

Mechanical effects of thrombus material in an LVAD

generated by the pump; patient-related owing to pro-thrombotic

If thrombus material becomes lodged in the space between the ro-

conditions including elevated blood pressure, infection, congestive

tating impeller and the stationary pump housing (Figure 1), energy

heart failure and hypercoagulable states; and management-related

will be lost due to friction (Potapov et al., 2017). To overcome this

factors resulting from subtherapeutic and inadequate anticoagu-

loss in energy, more power is required in order to maintain the pre-

lation (Cook et al., 2017; Kilic et al., 2015). Patients with bleeding

set rotational speed. As a result, pump thrombosis may lead to false

events such as gastrointestinal bleeding are predisposed to a higher

high flow readings. Most rotary blood pumps estimate the flow gen-

risk of thrombosis owing to the need of decreasing or discontinuing

erated by the pump from its power consumption reading. To com-

anticoagulation (Kilic et al., 2015).

plicate the situation, the combined effect of low flow and increased

Pump thrombosis is associated with increased morbidity and

power may compensate for each other, resulting in unsuspicious

mortality if not promptly and effectively managed. Elevated lactate

flow readings despite thrombotic material causing both flow reduc-

dehydrogenase can occur up to 3 months prior to pump thrombosis

tion and power increase (Potapov et al., 2017). This could be fatal, if

which can be monitored routinely as a biomarker for haemolysis and

it goes undetected over a period of time.

pump thrombosis, which may help in early detection and thus management (Kilic et al., 2015; Starling et al., 2014).

Effects on the corpuscular blood components
Thrombi which are located at highly sensitive areas in LVADs, such
as regions of turbulent flow velocities or high shear stress often in-

3.1.1 | Hydrodynamic effects of thrombus material
in an LVAD

creases the shear rate and thus haemolysis (Potapov et al., 2017).
Haemolysis may be used as an indicator of pump thrombosis, even
in cases of minimal alterations in flow or power consumption. As a

A considerable size thrombotic material may cause a narrowing

general rule, the presence of haemolysis mandates hospital admis-

of the flow path in one or more sections of the LVAD, resulting in

sion and further diagnostic testing. Haemolysis leads to an elevated

the reduction of LVAD's pumping capacity, due to elevated flow

risk of LVAD-related adverse events, resulting in increased morbid-

resistance (Potapov et al., 2017). Clinically, this would lead to

ity and mortality (Potapov et al., 2017).
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Positioning of LVAD inflow and outflow graft cannulas

four fixation methods, depending on whether “Core-then-Sew” or

According to the 2019 European Association for Cardiothoracic

“Sew-then-Core” technique is used: (1) Epicardial (2) Transmural

Surgery (EACTS) Expert Consensus, the placement of inflow cannula

(3) Transmural with or (4) without back stitch. Epicardial stitching

is preferred in the LV apex and anterior wall (Potapov et al., 2019).

of the sewing ring showed the best outcome of pump stabilisation

Positioning of inflow cannula is important in preventing the can-

along with a reduction in risk of thrombus formation and bleeding.

nula from penetrating too deep into the LV chamber. Such error can

On the contrary, transmural without back stitch proved to be the

impact the LV hemodynamics and unloading, which may increase

least beneficial as the sutures were exposed to the blood through

the risk of pump thrombosis (Chivukula et al., 2018; Chivukula

having a gap around the cannula which posed a high risk of thrombus

et al., 2019). The Standard approach for placing the inflow cannula

formation (Hanke et al., 2017). Schmitto et al. utilised a less invasive

involves a full median sternotomy for the LV apex inflow cannula

approach and implanted HeartMate 3 via an upper hemi-sternotomy

and ascending aorta outflow graft (Potapov et al., 2019). Compared

combined with an anterior lateral thoracotomy approach. The pump

to the standard approach, a sternotomy-sparing technique, for ex-

was inserted into the left ventricle through an apical cuff and the

ample, left lateral thoracotomy, allows for direct access to the apex,

outflow graft was anastomosed end-to-side to the ascending aorta

which promotes better inflow cannula placement. This results in

(Schmitto et al., 2018).

better pump durability and helps in lowering the risk of pump throm-

The standard site for inserting the outflow cannula is the as-

bosis (Cheung et al., 2011; Maltais et al., 2018). While sternotomy-

cending aorta (Potapov et al., 2019). Using this insertion site requires

sparing approach is preferable, as it is less invasive and decreases

accurate angling with appropriate prolene running sutures to allow

the risks of postoperative complications, for example, bleeding, tho-

for proper directional flow of the blood to reduce haemodynamic

racic wall instability etc., this approach requires the surgeon to be

stress on the aortic root wall and aortic valve. Appropriate inser-

confident with apical coring and alternative outflow graft manage-

tion practice reduces the incidence rates of aortic regurgitation

ment, hence, it has a learning curve associated with it (Krabatsch

(Bouabdallaoui et al., 2018). Having said that, the development of

et al., 2014; Maltais et al., 2014).

aortic insufficiency is one of the challenges faced after success-

While the apex is favoured for LVAD inflow cannula insertion,

ful LVAD implants. Though it is manageable through concomitant

anatomical complications such as apical aneurysm can restrict its

aortic valve replacement, it poses a risk of recurrent heart failure

use as a preferred insertion site. The inferior LV wall could be an

and remains a clinical challenge to treat after an LVAD implanta-

alternative graft site when surgeons are challenged with a geomet-

tion (Bittner, 2018). A useful method to reduce LVAD-related aor-

rically impaired dilated LV and apical aneurysm (Loforte et al., 2021;

tic insufficiency in patients with competent valves or even existing

Potapov et al., 2019). In cases where challenged with hypertrophic

mild to moderate aortic insufficiency would be a simple coaptation

cardiomyopathy, thin ventricle walls and/or LV wall calcification, left

stitch of the valve (Park et al., 2004). The ascending aorta should be

atrium (LA) is mandated as an inflow cannula graft site (Kiamanesh

avoided in case of heavy calcification, pseudoaneurysms or a hostile

et al., 2020; Osaki et al., 2009). Figure 3 shows the inflow cannula

mediastinum, due to any previous surgery or mediastinum infec-

insertion sites for the LVADs.

tion (El-Sayed Ahmed et al., 2014; Potapov et al., 2019). Surgeons

Anchoring method also appears to play an important role in

should pre-operatively, decide upon alternative sites for outflow

the prevention of thrombus formation. An in vitro study tested

cannula placement, such as descending thoracic aorta, supra-celiac

F I G U R E 3 Illustration showing LVAD inflow cannula configurations from left lateral view. LVAD inflow cannula configurations. LVAD, left
ventricular assist device
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abdominal aorta, brachiocephalic (innominate) artery, left axillary

ischaemic and haemorrhagic stroke are implicated but the incidence

artery or subclavian arteries (El-Sayed Ahmed et al., 2014; Kar

of an ischaemic stroke is higher than a haemorrhagic stroke with an

et al., 2005). Table 1 lists some of the reasons for using different

annual incidence of 5.5% versus 3.1%, respectively (Han et al., 2018).

outflow graft cannulation sites.

Thrombus deposition at the pump, aortic valve or on inflow or out-

Various outflow cannulation sites are shown in Figure 4.

flow grafts give rise to an ischaemic stroke while haemorrhagic
stroke happens secondary to endocarditis, elevated blood pressure
or haemorrhagic conversion of ischaemic infarcts (Han et al., 2018).

3.2 | Stroke

MOMENTUM 3 trial established that a fully magnetically levitated
continuous flow centrifugal pump (HeartMate 3) displayed a lower

Stroke is another relatively frequent complication that is associated

prevalence of stroke compared to continuous-flow axial mechanical

with LVADs that increases the mortality risk. It has been estab-

bearing pump (HeartMate II) at 2 years (10.1% vs. 19.2%, p = 0.02)

lished that 13%–30% of patient on LVADs experience a stroke (Han

(Mehra et al., 2018). This is a result of the enhanced design of the

et al., 2018; Rogers et al., 2017). The eighth annual INTERMACS

pump which reduces stasis by having an intrinsic pulsatility and also

report reported that 18,591 LVAD devices had been implanted in

reduces shear stress due to wider blood-flow paths thus significantly

patients in America by the end of 2016 (Kirklin et al., 2017). Both

reducing the risk of pump thrombosis (Mehra et al., 2018).

TA B L E 1 Outflow cannula insertion site for LVADs

3.3 | Bleeding

Outflow cannula
insertion sites

Reasons

Bleeding, mainly manifesting as gastrointestinal bleeding and

Ascending Aorta

Standard practice and preferred site

epistaxis, is another complication following LVAD implantation (Han

Descending thoracic
aorta

Unviable ascending aorta

et al., 2018). The strict balance of the haematological system is dis-

Cases of re-entry (REDO) patients with
hostile mediastinum

the blood products and the device surface leading to thrombosis

Supra-celiac
abdominal aorta

Unviable thoracic aorta

Innominate artery

For less invasive procedure

Axillary artery

Unviable thoracic aorta

REDO patients with hostile mediastinum

REDO patients with hostile mediastinum

turbed when an LVAD is implanted due to the interaction between
or bleeding. Factors that increase the risk of bleeding with LVADs
include impaired platelet aggregation, anticoagulation, low pulsatility and shear stress resulting in acquired von Willebrand syndrome,
arteriovenous malformations and mucosal ischemia, particularly
with gastrointestinal bleeding. 15%–30% of patients experienced
gastrointestinal bleeding following LVAD implantation (Goldstein

F I G U R E 4 LVAD outflow cannula configurations. LVAD, left ventricular assist device
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et al., 2015; Stulak et al., 2014). Management includes initiating

surface, rapidly converting the implant into a biologically recognis-

proton pump inhibitors, administering blood products as necessary

able material (Biran & Pond, 2017).

and reducing or temporarily discontinuing anticoagulation while
closely monitoring as this would increase the risk of thrombosis
(Han et al., 2018; Kilic et al., 2015).

3.4 | Von Willebrand syndrome

3.5.2 | Platelet adhesion
Platelet activation may be elicited by a variety of mechanisms, including device-related alteration in blood flow that triggers shear-
related platelet activation, and due to the adherence of circulating

Von Willebrand factor (vWF) is a protein involved in haemostasis

platelets to the adsorbed protein layer on the biomaterial surface,

which helps in platelet aggregation and sticking to damaged blood

an event largely attributed to adsorption of fibrinogen (Biran &

vessels to form a clot. VWF multimers bind to the collagen on dam-

Pond, 2017; Lavery et al., 2017).

aged blood vessels, then platelets bind to the VWF causing plate-

Fibrinogen is the primary protein responsible for platelet adhe-

let activation, adhesion, aggregation and thrombosis to prevent

sion. The platelet-fibrinogen interaction is mediated by the glycopro-

bleeding (Geisen et al., 2008). Acquired von Willebrand functional

tein GPIIb/IIIa receptor, the most abundant integrin on the platelet

deficiency syndrome, specifically type 2A which is associated with

surface. Ordinarily, GPIIb/IIIa receptors on circulating platelets must

LVAD devices, occurs as a result of the high local shear stress and

be conformationally activated via inside-out signalling before it is

blood flowing over the non-biological surfaces of the device which

capable of binding to adsorbed fibrinogen (Jaffer et al., 2015). While

increases platelet activation (Sisti et al., 2020). The increased shear

the exact mechanism remains elusive, GPIIb/IIIa receptors may de-

stress causes structural changes in the shape of the vWF expos-

tect and bind irreversibly to fibrinogen, even in their quiescent state

ing the bonds between the amino acids thus leading to proteolysis

(Jaffer et al., 2015, Lavery et al., 2017).

of the highest molecular weight multimers of vWF which are the

Once activated, platelets undergo a dramatic change in shape,

most active in haemostasis by the enzyme ADAMTS-13 (Adatya &

triggering a series of complex biochemical pathways, culminating

Bennett, 2015). Furthermore, the increased shear stress strength-

in the release of pro-coagulant agonists such as adenosine diphos-

ens the effect of ADAMTS-13 on VWF breakdown and increases its

phate (ADP), thromboxane A2, calcium ions, p-selectin and various

activity. This results in the reduction in high molecular weight VWF

coagulation factors (including coagulation factor V) from intracellu-

multimers in patients post-LVAD implantation leading to impaired

lar granules, which collectively amplify the cycle of platelet activa-

haemostasis and bleeding in 30%–75% of patients with continuous-

tion and attachment, and support cross-t alk with the coagulation,

flow LVADs (Adatya & Bennett, 2015).

complement and immune systems (Lavery et al., 2017; Wiegner
et al., 2016). Platelet aggregates formed through these diverse path-

3.5 | Pathophysiology of pump thrombogenesis
3.5.1 | Protein adsorption

ways associated with fibrin to form a platelet-fibrin thrombus on the
biomaterial surface, as shown in Figure 2 (Lavery et al., 2017).

3.5.3 | Activation of the coagulation cascade

Initial device contact immediately disrupts natural blood homeostasis, with the biomaterial surface immediately becoming coated

Components of the blood contact system adsorb to the artificial

with a thin boundary layer interphase of adsorbed plasma pro-

surfaces of the LVAD, which facilitates the activation of the in-

teins, with a thickness in the order of 2–10 nm (Jaffer et al., 2015;

trinsic pathway of coagulation, eventually culminating in the for-

Wilson et al., 2005). The rapid process (<1 s) of protein adsorption

mation of fibrin. The interplay between platelets and the clotting

is widely regarded as the initiating event in thrombus formation

cascade has also been identified wherein activated platelets release

since this protein layer is responsible for mediating many subse-

pro-coagulant proteins (factor V) and intermediate clotting factors

quent reactions (Jaffer et al., 2015; Mulzer & Brash, 1989; Santerre

generated in the coagulation cascade are potent platelet activators

et al., 1992; Wilson et al., 2005). The dynamics of protein adsorp-

(thrombin) (Abrams, 2006; Sukavaneshvar, 2017).

tion are related to the chemical and physical properties of the

The biochemistry and molecular biology of these major processes

surface and the proteins (Jaffer et al., 2015; Lavery et al., 2017).

have been studied extensively for decades (Sukavaneshvar, 2017,

Thus, adsorption involves interactions between charged groups at

Ham Tran, 2006, Bates & Weitz, 2006). Figure 5 shows a simplified

the protein–surface interface and/or conformational changes in

illustration of thrombus formation on the biomaterial surface via ac-

protein structure. Surface adsorption is a reversible process, and

tivation of the coagulation cascade. Recognition of the important

the composition of the adsorbed proteins changes over time, a

role of the contact activation pathway to induce thrombus formation

phenomenon is known as the Vroman effect (Jaffer et al., 2015).

against biomaterial surfaces has led to attempts to use pharmaceu-

Pro-thrombogenic plasma proteins, such as fibrinogen, vWF and fi-

tical agents inhibiting the initiation of the intrinsic blood coagulation

bronectin, are among the first proteins to deposit on the artificial

cascade. As a result, fXII and fXI have emerged as promising targets

MALONE et al.
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F I G U R E 5 Simplified illustration of thrombus formation on biomaterial surface via activation of the coagulation cascade. Activation of the
intrinsic pathway of coagulation culminates in the formation of fibrin

for the prevention of thrombosis on blood-contacting devices (Biran
& Pond, 2017).

Warfarin, a vitamin K antagonist, is the main anticoagulant used
post-LVAD implantation. Warfarin is a coumarin anticoagulant which

Anticoagulants such as heparin, rivaroxaban, and dabigatran

inhibits the vitamin K epoxide reductase complex 1 (VKORC1), an

and anti-platelet agents such as aspirin, thienopyridines and gly-

enzyme responsible for activating vitamin K, thus inhibiting the syn-

coprotein IIb/IIIa inhibitors are widely used drugs for the preven-

thesis of vitamin K-dependent coagulation factors II, VII, IX and X

tion of thrombosis in many clinical settings (Biran & Pond, 2017;

in addition to the anticoagulant proteins C and S (Patel et al., 2020).

Sukavaneshvar, 2017).

Warfarin does not have a direct effect on an established thrombus
but it prevents thrombosis and embolism. Warfarin is dosed based
on the results of the prothrombin time usually reported as the INR

3.5.4 | Anticoagulants used in patients with LVADs

(International Normalised Ratio). The target INR for patients on warfarin therapy post-LVAD implantation is 2–3 (Boehme et al., 2017).

Given the foreign nature of LVADs and its interaction with blood

The time spent in this INR range is important to reduce the risk of

products which can affect the body's strict haemostatic control

thrombus formation or bleeding. A study conducted to examine the

leading to thrombus formation and thus to increased morbidity and

Proportion of Time spent in Target Range (PTTR) of INR 2–3 in pa-

mortality in LVAD-implanted patients, anticoagulation and antiplate-

tients with LVAD devices demonstrated that patients remained in

let therapy are warranted. Two types of clots have been found to

the target range of INR 2–3 only 42.9% of the time indicating low

occur in LVADs: (i) red clots, which are rich in red blood cells, and

anticoagulation control despite the rigorous anticoagulation and

may be associated with blood stasis due to flow conditions or inad-

LVAD management (Boehme et al., 2017). Furthermore, compared to

equate anticoagulation regimes, and (ii) white clots, which are rich in

unfractionated and low molecular weight heparin, warfarin carries

platelets with a fibrin mesh, that forms over time (Shah et al., 2017).

a lower thromboembolic risk (Rossi et al., 2012). As for antiplatelet

Anticoagulation and the use of antiplatelet therapy are recom-

therapy, aspirin is the main antiplatelet used at a dose of 81–325 mg/

mended for all patients implanted with an LVAD, however, the spe-

day alone or in combination with second antiplatelet dipyridamole

cific approach utilised differs across different mechanical circulatory

or clopidogrel. Antiplatelets are used to prevent thrombus forma-

support centres (Rimsans et al., 2016; Sage et al., 2018).

tion caused by the activation of platelets as a result of the shear
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eptifibatide, antithrombotics, pump replacement or explantation

faces (Jennings & Weeks, 2015). Combining oral anticoagulants with

(Rimsans et al., 2016; Rogers et al., 2017). These practises are sum-

antiplatelet therapy increases the risk of bleeding and thus close

marised in Figure 7.

monitoring is required.

In 2014, Najjar et al. analysed the incidence of pump throm-

A ‘one size fits all’ approach cannot be applied to anticoagulant

bus in the 382 patients who received an HVAD under the BTT and

and antiplatelet management therapy with LVAD patients as differ-

CAP protocols (Levine & Gass, 2019; Najjar et al., 2014). The effec-

ent device types and pump flow have different indications and re-

tiveness of various treatment strategies and predisposing factors

quirements in addition to individual patient factors which impact the

to the development of pump thrombus was also evaluated (Najjar

response to anticoagulants and antiplatelets and thus the manage-

et al., 2014). Three hundred eighty-t wo patients were involved in

ment approach. For example, early post-operative anticoagulation

the study who had the HVAD device implanted, of these 8.1% ex-

management for HeartMate II, implantable centrifugal pumps and

perienced pump thrombosis and 4.2% required pump replacement

pulsatile MCS devices are primarily based on expert opinions pub-

(Najjar et al., 2014). Patients were successfully managed with medical

lished in 2013 that detail the recommended haemodynamic man-

therapy in 50% of thrombus case, which consisted of heparin, glyco-

agement in these patients and are summarised in Figure 6 (Feldman

protein (GP) IIB/IIIA inhibitors, for example eptifibatide and alteplase

et al., 2013).

(tPA) used alone or in combination. It was found that alteplase (tPA)

An individualised approach to therapy is required to balance

successfully treated pump thrombosis in 63% of patients, eptifi-

the risk of thrombosis and bleeding (Adatya & Bennett, 2015).

batide used alone or in combination with heparin succeeded in 50%

Essentially, it has been established that having an INR < 2 and a sub-

of patients and the use of heparin alone was not successful (Najjar

therapeutic dose of aspirin increases the risk of thrombosis but this

et al., 2014). While these findings provide support for the role of

should balance the risk of bleeding (Adatya & Bennett, 2015).

medical therapy in managing pump thrombosis, the small number
of thrombosis events and the heterogeneity of therapies used make

4 | M A N AG E M E NT O F LVA D PU M P
TH RO M B OS I S

it difficult to make strong inferences about preferred strategies for
the management of pump thrombosis (Najjar et al., 2014). Additional
studies are needed to gain a deeper understanding of the preferred
regimen, dosage and duration of medications that will provide the

As mentioned earlier, pump thrombosis is one of the main complica-

optimal balance between efficacy and safety. Multivariable analy-

tions that arise post-LVAD implantation that affects morbidity and

sis revealed various risk factors for pump thrombus, including sub-

mortality and can lead to the requirement for either LVAD device

therapeutic international normalised ratio (INR > 2), sub-optimal

replacement or explantation. Elevated lactate dehydrogenase can

anticoagulation and antiplatelet therapy-elevated mean arterial

occur up to 3 months prior to pump thrombosis which can be moni-

blood pressure < 90 mmHg (Najjar et al., 2014).

tored routinely as a biomarker for haemolysis and pump thrombosis

Bivalirudin is an alternative anticoagulant to heparin that is ad-

early detection and thus management (Rogers et al., 2017). Pump

ministered intravenously which interacts with both free and clot

thrombosis can be caused by both a red thrombi which is a fibrin

bound thrombin and reversibly inhibits it thus inhibiting the activa-

mesh with trapped red blood cells that develops rapidly or a white

tion of factors V, VIII, XIII and protein C and is less immunogenic

thrombi which is aggregated platelets and debris that develops

compared to heparin thus avoiding heparin-induced thrombocy-

slowly over time. Since they are composed of different components,

topenia (HIT) (Adatya & Bennett, 2015; Rimsans et al., 2016). An

thrombolytic treatment would be successful with a red thrombus

algorithm for the diagnosis and management of suspected pump

while white thrombus would respond better to glycoprotein (GP)

thrombosis constructed by a multidisciplinary team and published by

IIB/IIIA inhibitors (Adatya & Bennett, 2015). Pump thrombosis is

the international society for heart and lung transplantation working

managed in numerous ways, which include increasing the intensity

group detailing the proposed algorithm according to the clinical pre-

of anticoagulants and antiplatelets; initiating antiplatelet therapy;

sentation of the patient has been developed as a potential guide that

initiating thrombolytic agents like fibrinolytics, for example al-

can be adhered to in order to manage pump thrombosis in patients

teplase (tPA) and glycoprotein (GP) IIB/IIIA inhibitors, for example

(Goldstein et al., 2013).

F I G U R E 6 Recommended haemodynamic management for patients after receiving the axial-flow HeartMate II LVAD. LVAD, left
ventricular assist device
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F I G U R E 7 Summary of anti-thrombotic management for left ventricular assist devices. GI, gastrointestinal; GP, glycoprotein; LVAD, left
ventricular assist device; PPI, proton pump inhibitor

It should be noted that pharmacological management of pump

5.1 | Passive coatings

thrombosis is associated with a high proportion of treatment failure eventually leading to the need for pump replacement (Adatya &

5.1.1 | Diamond-like carbon

Bennett, 2015). Pump replacement is required in patients with obvious pump thrombosis, pump blockage and in shock, unresponsive to

Diamond-Like Carbon (DLC) Coating is currently the most commonly

battery and controller exchanges without further diagnostic studies

used passive coating, being used on devices such as the VentrAssist

(Goldstein et al., 2013).

LVAD (Sin et al., 2012, Meer et al., 2003). This coating is formed from
a metastable form of amorphous carbon, which contains a signifi-

5 | COATI N G M ATE R I A L S FO R
M EC H A N I C A L C I RC U L ATO RY S U PP O RT
D E V I C E S TO M ITI G ATE B LO O D
COAG U LO PATH Y

cant amount of tetrahedral sp3 hybridised atoms, along with varying
amounts of hydrogen (Wagner et al., 2020). DCL films and coatings
may be easily deposited on a wide variety of substrates, through
chemical vapour deposition (CVD) and physical vapour deposition
(PVD), which have been reviewed in detail elsewhere (Fedel, 2013).
DLC coatings are characterised by their excellent mechanical, chemi-

Modification of medical device surfaces to improve blood compat-

cal and electrical properties, making them most appealing for bio-

ibility has been pursued to reduce device-related thrombus forma-

medical applications. When compared to other blood-interfacing

tion and inflammatory reactions. Surface modification technologies

materials, such as titanium alloy, polycrystalline diamond and ex-

can be assigned into two broad categories: (a) passivation of material

panded polytetrafluroethylene (ePTFE) (Jones et al., 2000; Schaub

surfaces and (b) bioactive surface treatments and coatings (Biran &

et al., 2000; Sin et al., 2012). DLC-coated surfaces demonstrate low

Pond, 2017; Tanzi, 2005). Passive approaches are aimed at reducing

levels of interaction with the immune system, clotting factors and

the inherent thrombogenicity of the material surface by establishing

platelets due to their hydrophobic nature, chemical inertness and

a barrier at the device-blood interface through modification of sur-

low frictional coefficient (Jones et al., 2000; Zeng et al., 2016). As

face chemistry (e.g. hydrophilicity) or material physical structure (e.g.

a result, DLC coatings may be applied to reduce the incidence of

topography). Bioactive strategies employ direct pharmacological in-

thrombosis.

hibition of the coagulation response by local drug delivery or perma-

A DLC coating was tested in vivo with the EVAHEART centrif-

nent immobilisation of an active agent (Sin et al., 2012; Tanzi, 2005).

ugal VAD (SunMedical Technology, Japan), maintaining a stable
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performance without any adverse effect over 6 months in calves

Examples of textured topographies include nano-dimples, nano-

under the postoperative anticoagulation protocol. Blood-contacting

fibers and microgratings. A variety of manufacturing technologies

surfaces of the DLC coating were entirely free from thrombus for-

exist that allow for controlled textured surfaces, at the nano- and

mation. The wear rate of the seal face was 10 μm after 200 days

micro-scale, including solid free-form machining, moulding, stereo-

of continuous operation, with no measurable wear at the hydrody-

lithography, laser machining and sintering (Bose et al., 2018). The

namic bearing (Wagner et al., 2020; Yamazaki et al., 1998).

HeartMate family of LVADs utilise inflow cannulae which are fully

One of the major limitations of this coating is the possible for-

textured with sintered titanium microspheres, along with textured

mation of micro-cracks on its surface, leading to increased internal

polyurethane linings. Textured polyurethane membranes also re-

stresses, followed by subsequent film breakdown (Zeng et al., 2016).

duce the adhesion of the pathogen Staphylococcus aureus, thereby

If adhesion is insufficient, the coating may spontaneously delaminate

reducing the risk of device infections (Bose et al., 2018; Noviani

as a result (Zeng et al., 2016). To counter this, modified DLC coatings

et al., 2016; Shah et al., 2017).

with elastic features are being researched (Shirakura et al., 2006; Sin
et al., 2012).

It is important to note that not all textured surfaces lead to
the production of a neo-intimal layer formed exclusively from endothelial cells. In 1993, Salih et al reported the presence of at
least two different cell populations on the textured surfaces of

5.1.2 | 2-methacryloyloxyethyl phosphorylcholine

ThermoCardiosystems LVADs (Salih et al., 1993). Therefore, endothelial progenitor cell deposition onto the blood-contacting surfaces

Coating surfaces with zwitterionic films is an effective method

may be considered to induce or trigger the formation of an endothe-

of enhancing the biocompatibility of an implantable device

lial layer. Alternatively, textured surfaces may also be seeded with

(Schlenoff, 2014). Phosphatidylcholine, the major phospholipid found

endothelial cells, followed by in vitro culture prior to implantation,

on the outer surface of the mammalian cell membrane resists cell

which will be explored in the later sections (Sukavaneshvar, 2017).

and protein adhesion due to its zwitterionic polar head group being
electronically neutral at physiological pH. 2-methacryloyloxyethyl
phosphorylcholine (MPC) polymer incorporates the phosphatidyl-

5.2 | Active coatings

choline head group within its polymer backbone, and thus, effectively suppresses thrombin formation and the associated adsorption

One strategy to address the challenge of pump thrombosis using

and activation of platelets, even in the absence of anticoagulants,

anti-thrombogenic drugs without increasing bleeding risk is

rendering it as anti-thrombogenic (Ishihara, 2019; Jaffer et al., 2015).

the surface modification of the device biomaterial surface with

The EVAHEART® LVAD consists of a titanium pump, modified with

anti-thrombogenic drug molecules (Jordan & Chaikof, 2007;

a coating of MPC polymer on all blood-contacting surfaces in order

Sukavaneshvar, 2017). The aim of this approach is to localise the

to maximise hemocompatibility.
However, the MPC polymer has been found to be biodegradable,
and as a result, the anti-thrombogenic properties of MPC-coated

effect of the anti-thrombogenic drug around the device, without systemic suppression of necessary hemostatic function
(Sukavaneshvar, 2017).

material may possess a limited lifetime, meaning the patient will
eventually require antithrombotic therapy (Sin et al., 2012). A recent study by Kihara et al. found that after 45 days (±32 days), only

5.2.1 | Heparin

60% (±37.2%) of the pump surface was still coated with MPC (Kenji
et al., 2004).

Heparinization is the most popular technique for device surface
modification due to its potent anticoagulant properties (Biran &
Pond, 2017). Depending on its molecular weight and structure,

5.1.3 | Textured surfaces

heparin binds to antithrombin-III which is present in the blood
plasma, significantly increasing the potency of antithrombin-III's

Biomaterial surfaces serve as critical interfaces between the

to inactivate factor Xa and thrombin that may be generated on

host and implant to coordinate many biologic processes (Wagner

the device surface (Biran & Pond, 2017). Since these clotting

et al., 2020). Historically, medical devices that incorporate textured

factors are key mediators of thrombosis, their inactivation lim-

blood-contacting surfaces have shown greater biocompatibility than

its device thrombosis. Moreover, since thrombin is also a potent

smooth constructs. This is because the textured surfaces promote

platelet activator, the presence of heparin-binding heparin into an

the adhesion of circulating endothelial cells to form a stable ‘ne-

inactive complex should help minimise platelet activation, lead-

ointimal’ lining, which minimises thromboembolic risk and reduces

ing to improve hemocompatibility of the implant material (Wagner

the level of required anticoagulation therapy (Wagner et al., 2020).

et al., 2020).

Similarly, the textured surface increases the constructed surface

Investigators have been able to covalently, ionically and phys-

area, creating space for cells to attach and proliferate (Wagner

ically attach heparin to various substrates utilising a number of

et al., 2020).

chemistries.

|

MALONE et al.

15

5.2.2 | Ionically bound heparin

5.2.4 | Limitations of heparin-binding

Ionic approaches involve binding the highly negatively charged

Despite these promising attributes, LVADs coated with heparin have

heparin onto a cationic surface through ionic binding, with hepa-

not been associated with significant reductions in thromboembolic

rin being slowly released into the bloodstream. However, a seri-

events. This is due to the fact that heparin is only an anticoagulant

ous limitation of ionic bonding is the risk of leaching of heparin,

and not an antiplatelet agent (Sukavaneshvar, 2017). This limitation

which will eventually leave the surface unprotected (Wagner

is particularly relevant in LVADs, where platelets play a major role in

et al., 2020).

thrombus development, that is where high shear and disturbed flow
lead to platelet activation and aggregation even in the presence of
anticoagulants (Sukavaneshvar, 2017). Moreover, due to its biode-

5.2.3 | Covalently bound heparin

gradable nature, heparin coatings have a finite lifespan, which is in
contrast to DLC coatings. As a result, this drug-device combination

To impart a degree of activity longer than that possible with

has not eliminated the need for systemic anti-thrombogenic drug

ionic linkages, covalent chemistries were developed to im-

usage to minimise the risk of pump thrombosis. Considering the mul-

mobilise heparin onto the surface (Wagner et al., 2020). While

tifactorial nature of device thrombosis, it is not surprising that strat-

several variations of surface immobilised heparin have been de-

egies aimed at inhibiting one step of the thrombotic process have

veloped, which utilise diverse linker chemistries it is now rec-

not succeeded entirely and hybrid concepts that incorporate two or

ognised that the conformation of the attached heparin and the

more anti-thrombogenic properties are being increasingly explored

point of attachment (end point vs. multipoint) are critical factors

(Lih et al., 2016; Wang et al., 2013).

determining the catalytic efficiency of the immobilised heparin
(Sukavaneshvar, 2017). Some of the notable examples of commercial coatings making use of covalent bonding are Carmeda

5.2.5 | Endothelial cell lining

BioActive Surface (CBAS) from Medtronic, which is used on devices such as the Berlin Heart INCOR LVAD, and Trillium, devel-

The endothelial cell presents and releases a number of biologi-

oped by BioInteractions Ltd.

cally active agents that limits thrombogenesis in vivo. As such, ap-

Carmeda BioActive Surface consists of depolymerized, lower

proaches to mimic these properties, such as seeding or otherwise

molecular weight heparin covalently grafted to biomaterial surfaces

reconstituting endothelial cells on the surface of the LVAD are

by aminating the base matrix, which consists of positively charged

been actively pursued as a method of enhancing biocompatibility

polyethyleneimine and negatively charged dextran sulphate de-

(Sukavaneshvar, 2017). The use of endothelial cell linings remains

posited in a layer-by-layer fashion. This method was developed by

controversial as it does not work in areas of pump with small clear-

Larm et al (Larm et al., 1983). What is unique to Carmeda Bioactive

ances. These surfaces may also partially lose function over time, or

Surface is that it retains the functional activity of the immobil-

may wash away with blood flow. Extraction of the epithelial cells

ised heparin, specifically its capacity to bind to the coagulation

and texturing of the surfaces is difficult, creating further challenges

inhibitor anti-thrombin, present in the bloodstream (Hosseinipour

these coatings. They also offer no guarantee of function, as cells may

et al., 2017; Larm et al., 1983). Inactive complexes formed on the

wash away by the blood upon implantation (Sin et al., 2012).

immobilised heparin are released and swept away by the blood

Each different surface coating comes with its own benefits and

flow and excreted. As a result, covalently bound heparin is not con-

its own challenges. The current challenge is to produce an MCS de-

sumed in the reaction but remains active and available for further

vice with an optimal design and coating combinations as to offset

inhibition.

downfalls and compound benefits.

Trillium, developed by BioInteractions Ltd. and marketed by
Medtronic, is a tri-functional polymer coating, which provides
endothelial-like characteristics to the surface of the VAD. A priming
layer is first bound to the blood-contacting surface, followed by the
deposition of a hydrophilic functional layer with covalently bound

6 | D E V I C E D E S I G N I M PROV E M E NT
TO M ITI G ATE LVA D - R E L ATE D B LO O D
COAG U LO PATH Y

heparin (Hosseinipour et al., 2017). Sulphate and sulfonate groups,
which are incorporated into the functional layer emulate the nega-

The HeartAssist5 is the modern version of DeBakey/NASA VAD that

tive charge of the vascular endothelium. These negatively charged

has been under development since 1988 (Agarwal & High, 2012;

polymers repel negatively charged platelets, preventing platelet ad-

Hosseinipour et al., 2017). A unique feature of the HeartAssist 5

hesion and activation. Polyethylene oxide polymer, which is present

device is the addition of an integrated ultrasonic flow probe around

within the functional layer is hydrophilic in nature, thereby creating

the outflow graft that collects real-time measurements of blood

an insulating water layer between the blood and artificial surface

flow as it moves from the outflow graft into the aorta (Hosseinipour

that resists cell adhesion and protein deposition (Biran & Pond, 2017;

et al., 2017). Pump parameters, including pump flow (L/min), power

Hosseinipour et al., 2017).

consumption (watts) and pump speed (rpm), are also recorded, which
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provides the physician with real-time information on the patient's

with speed modulation technology, which uses rapid changes in

cardiac activity, and will alert them in instances of unusual activity.

rotor speed every 3 seconds to mimic an intrinsic, physiological pulse

Extensive work has been carried out to refine the pump geometry in

(Levine & Gass, 2019). The pump is composed of sintered titanium

order to maximise hemocompatibility. Through careful study of the

microspheres, which establish an endothelial tissue interface at the

system's computational fluid dynamics, much optimisation has been

boundary of the device.

done on refining the internal geometry of the pump, such that blood
is drawn smoothly through the LVAD resulting in less platelet activation and hemolysis. The impeller, flow straightener and diffuser
are designed such that they eliminate any area of blood stagnation,

7 | RO LE O F S H A PE M E M O RY A LLOY
M ATE R I A L S I N A N C H O R I N G O F LVA D

thereby preventing thrombus formation. All blood-contacting surfaces are made of highly polished titanium with Carmeda BioActive

As we are moving towards less invasive techniques of LVADs im-

Surface coating, which is known for its excellent biocompatibility

plantation, the anchoring mechanism plays a crucial role in the

(Hosseinipour et al., 2017).

stabilisation of the device and prevention of thrombus formation.

In line with other third-generation LVADs, the DuraHeart LVAD

Future holds for miniaturised LVADs that may be delivered via a

incorporates a centrifugal flow rotary pump with a magnetically

transcatheter delivery system, without giving any incision on the

suspended impeller to provide long-term durability (Agarwal &

body. Shape memory alloys have been a burgeoning technological

High, 2012). The system is also supported by a secondary hydro-

field. Their benefit in medical and other commercial applications lies

dynamic bearing in the event of the magnetic system failing. What

in their mechanical characteristics, particularly their shape memory

makes the DuraHeart unique is the utilisation of three electromag-

abilities. There are many iron and copper-based alloy combinations

netic coils and position sensors to precisely control the impeller's

available, however, nickel-titanium (NiTi) alloys are most often used

position within the pump housing (Agarwal & High, 2012). The large

due to better stability, biocompatibility and performance (Jaronie

gaps between the impeller and the blood chamber walls (250 mi-

Mohd Jani et al., 2014, Morgan, 2004). These contain a composi-

crons on each side) enable improved washout, preventing throm-

tion of approximately 50% of both nickel and titanium. NiTi has been

bus formation inside the pump chamber. These gaps also translate

used in widespread industrial markets since its development and

into reduced shear stress and a corresponding hemolysis reduction.

began to be used in medical devices in the 1980s (Levi et al., 2008).

The pump's blood-contacting surfaces are made of both titanium

While nickel is a common allergen, and titanium has historically been

and stainless steel, with an additional coating of stable covalently

used in medical implants, in combination, as nitinol, these have been

bound heparin to enhance blood compatibility and reduce the risk of

found to be biological inert (Levi et al., 2008; Morgan, 2004). This is

thrombus formation in low-flow areas (Agarwal & High, 2012).

an important feature of the materials as, throughout their functional

The HVAD pump was also revolutionary in its application of

period, they need to have little to no effect on the biological system

magnetic suspension and hydrodynamic thrust bearing technol-

in which they operate, to avoid any allergic reactions or corrosion

ogy to support the impeller within the pump housing (Chatterjee

leading to the release of ions into the bloodstream (Jaronie Mohd

et al., 2018). Briefly, the impeller is passively suspended by magnets

Jani et al., 2014, Machado & Savi, 2003). This allows them to have

located within the pump, while hydrodynamic thrust bearings which

potential in the delivery, long and short-term use, and removal of

are located on the four wide-channel impeller blades provide the

devices.

necessary axial forces to balance the impeller's position within the

The properties that define shape memory alloys are their abil-

pump housing (Chatterjee et al., 2018). Its wide-blade impeller fea-

ity to be manipulated in and out of their original shape and/or size,

tures three blood flow paths, which are designed to enhance blood

as triggered by various influences such as temperature or magne-

flow and reduce blood trauma while reducing the blood travel time

tism (Jaronie Mohd Jani et al., 2014). Nitinol, in particular, can eas-

through the device (Chatterjee et al., 2018). The device possesses

ily be made compact through compression, in order to fit into even

an integrated inflow cannula which minimises the pump footprint

smaller dimensions than similarly elastic materials. Furthermore, it

within the chest cavity, allowing the pump body to be implanted en-

has the elastic properties to reorganise into its functional design

tirely within the pericardial space, eliminating the need for a pump

(Levi et al., 2008). This can be designed as an automated process

pocket. The pump housing is composed of titanium and the thermo-

as the materials are ‘trained’ to undertake certain forms under cer-

plastic polyester ether ketone, for improved durability (Agarwal &

tain conditions by an external force. Through this property they

High, 2012).

have found the most use as actuators in medical devices, acting

The most recent LVAD introduced for clinical use is the

as the component primarily responsible for the support and con-

HeartMate 3. This third-generation pump was designed with a focus

trol of the device's deployment and action. (Jaronie Mohd Jani

on mitigating the risk of thrombosis as seen with its predecessor,

et al., 2014) The nitinol material is set into its desired shape (a

the HeartMate II (Hosseinipour et al., 2017; Levine & Gass, 2019).

‘trained’ formation) by applying a crystallisation temperature of

The centrifugal pump utilises full magnetic levitation to maintain its

approximately 500°C and then rapid cooling (Levi et al., 2008).

impeller within the blood path, with wide blood flow passages to

At low temperatures, nitinol takes on the martensite phase and

reduce shear stress. This updated design is also pre-programmed

is very malleable, as the low-temperature results in a low-e nergy,

|
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symmetrical border configuration (Aaronson et al., 2012). In these

to its size and shape (Varela et al., 2019). The advancements in the

conditions, the material is condensed into the size and form nec-

utilisation of such materials in cardiovascular devices look promising,

essary for its implantation. Once in conditions of increased tem-

as they have huge potential to be used as an anchoring system for an

perature, such as when heated to internal body temperature upon

MCS device like an LVAD and eventually an incisionless procedure,

implantation, the structure transforms to the austenite state,

for example, via transcatheter delivery route. As described above

which, as a cubic structure, maintains the shape's stability in the

in Section 3.1.1.3, current implantation requires either sternotomy

trained formation (Levi et al., 2008; Machado & Savi, 2003). It will

or sternotomy-sparing procedures like left lateral thoracotomy. The

be maintained in the austenite state as long as the environment

LVAD is usually secured using sutures, however, with a transcathe-

remains stable as it can be reversed into the martensite phase via

ter delivery technique, nitinol can be used to anchor an LVAD from

low temperature or stress. This can include the stress placed on

inside the left ventricle. Furthermore, if device removal is required,

it by the work of the system that the material is placed in, which

instead of surgical removal, their shape memory feature may allow

results in a strain on the material. A significant advantage of the

the surgeons to remove the device via a transcatheter system.

shape memory designs is that they achieve an optimal stress–
strain balance in the austenite state, similar to that of human bone
and tissue (Morgan, 2004). This involves resisting compression
over a range of forces (that it may experience in a biological system) and recovering from them into their original shapes.

8 | C H A LLE N G E S I N PR E- C LI N I C A L
TE S TI N G O F M EC H A N I C A L C I RCU L ATO RY
SUPPORT DE VICE PUMP THROMBOGENICIT Y

The shape memory effect characteristics are what make
this resistance possible. Pseudo-elasticity, also known as super-

The International Organisation for Standardisation (ISO) defines

elasticity, is a shape memory effect characteristic demonstrated

guidelines pertaining to the evaluation of medical devices, derived

in alloys when heated above the temperature required to reach

from multiple national and international standards. In our evaluation

the austenite state (Jaronie Mohd Jani et al., 2014; Machado &

of MCS devices, it is important to acknowledge that these guidelines

Savi, 2003). Super elasticity is best achieved when the composition

for in vitro thrombogenicity tests differ depending on the device

of the nitinol has a slightly higher nickel content (Hord et al., 2019;

being assessed. In vitro studies can be subdivided into either static

Morgan, 2004). It allows the nitinol to take on a shape appropri-

models or dynamic models, with both subtypes coming with their

ate to the load, or stress, placed upon it when changes occur in

own inherent coagulopathic advantages and disadvantage (Sarode &

the system—such as in the changing diameter of a cardiac chamber

Roy, 2019). Static models are preferred for studying the interaction

during contraction. The two-way shape memory effect outlines the

between blood and material but are limited due to a lack of actual

mechanism through which the material returns to its trained shape,

blood flow. Dynamic models allow for a more complete analysis of

without mechanical loading (Machado & Savi, 2003). Instead, the

thrombosis with blood flow, however, they are highly unstandard-

phase transformations occur due to temperature changes, and the

ized (Sarode & Roy, 2019). These inherent differences pose a chal-

shapes formed after cooling and heating are distinct. For the mate-

lenge in the comparison and evaluation of MCS devices. There is a

rial to exhibit this characteristic it requires cyclic training wherein

lack of guidance on the use of testable markers for thrombosis in

the material is modified in and out of the martensite and austenite

static and dynamic models, and as a result, most thrombosis test-

phases under a variety of loads, in order to avoid stress-induced

ing occurs in vivo. While in vitro thrombosis testing does occur, it

phase transformations (Machado & Savi, 2003). However, this pro-

tends to be unstandardized. Most in vitro testing of MCS devices

cess does result in a less flexible re-arrangement of the crystalline

only measures haemolysis, and the focus of these tests tends to be

organisation—k nown as plastic strain—which has an irreversible

on the MCS devices operational performance, as opposed to a thor-

effect on the structure. The one-way shape memory effect occurs

ough evaluation of coagulopathy (Sarode & Roy, 2019). A thorough

when the material is shaped while in its cool, martensite phase

examination would study thrombosis, haemolysis, vWF levels, co-

by an external force. This stress placed by this force temporarily

agulation factor levels, etc. In vitro studies also require the use of

changes the materials crystal structure. It can then be reverted

an anticoagulant, which may not always be used in a clinical setting

back to its original form if it is heated—k nown as a reverse phase

(Sarode & Roy, 2019). Although the ISO guidelines are not intended

transformation (Machado & Savi, 2003).

to provide a rigid set of standards, there is a need for clearer guid-

A current widespread application of nitinol has been in the use of

ance and risk-management perspectives when it comes to the selec-

‘self-expanding’ stents wherein they are compressed into sheaths at

tion of materials and in vitro screening methods in the development

cold temperatures, deployed via catheter and expanded once heated

of MCS devices (Bernard et al., 2018).

to body temperature and their sheath is removed (Levi et al., 2008).

Many pro-thrombotic factors generated using in vivo studies are

Further, their use in cardiac support devices is still being explored

cleared from the blood and hence, detectable, giving this model an

with extensive possibilities. Cardiac compression devices have seen

advantage over in vitro study. However, in vivo studies also come

some of the greatest potential. The ParaCor HeartNet is a biven-

with their own pitfalls. They are expensive, time consuming and

tricular mesh restraint device comprised of nitinol that is designed

thrombotic markers can only be tested during symptomatic phases

to provide flexible support to a dilated heart, that easily conforms

of the disease, leaving no room for asymptomatic intervention
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(Sarode & Roy, 2019). While these studies can be useful, the results

While their benefits are indeed significant, pump thrombosis

do not always translate appropriately to humans due to physio-

remains the Achilles heel of LVADs. Current treatments for pump

logical differences between species (Sarode & Roy, 2019). Hence,

thrombosis consist of aggressive anticoagulation and antiplatelet

there is a need for a robust high-fidelity in vitro or ex vivo testbed

therapies, however, these therapies may be associated with in-

to test various aspects of intracardiac cardiac devices during their

creased risks of gastrointestinal bleeding. In cases of severe pump

developmental phase. Most recently, Park et al developed an orga-

thrombosis, device exchange or urgent transplantation may be re-

nosynthetic dynamic heart model whereby preserving the intracar-

quired. Due to the multifaceted nature of pump thrombosis, a ‘one

diac structures and replicating the left ventricular motion using soft

size fits all’ approach is not appropriate. An extended personalised

robotics (Park et al., 2020). These advancements are crucial for the

approach that incorporates the patient's unique hemostatic con-

development of novel intracardiac devices.

ditions is needed to balance the risk of bleeding and thrombotic

It is also important to note that the material used in an MCS device

complications. As such, understanding the predisposing risk fac-

is not the sole factor in MCS device suitability, and advancements of

tors for a pump thrombosis is critical to devising preventive strat-

MCS devices cannot be taken in isolation. While the biocompatibility

egies. Despite these obstacles, significant progress has been made

of the device is of high importance, we must consider the material

in methods to mitigate device thrombosis, particularly in the design

as a component of an MCS device, as opposed to a separate entity.

of pump geometry and surface modifications for blood-contacting

It is possible that the best choice of material with regards to its bio-

devices. Improved materials, combined with refined, personalised

compatibility may lessen the functionality of the MCS device itself.

drug regimens have reduced the risk of thrombosis, rendering many

Factors such as size, durability and shear stress produced as a result

devices clinically acceptable for a vast majority of patients.

of the machines function affect the suitability of a device for a given

Going forward, future MCS devices must focus their attention

patient. Coupling this knowledge with the known co-morbidities as-

on hemocompatibility and on individualised anticoagulation targets,

sociated with patients requiring an MCS device, it is clear that the de-

which are crucial for mitigating the occurrence of device thrombosis

cision to place a patient on a particular MCS device is multifactorial,

and improving the rates of overall patient survival. The lack of ro-

and as such should be decided on a case by case basis.

bust guidelines for the management strategy of pump thrombosis by

With regards to pump thrombosis, risk factors can be sub-divided

pharmacotherapy warrants further research in this area.

into patient, device and management-related factors. Patients requiring
MCS devices tend to be suffering from advanced-stage heart failure,
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